Genetic criteria for Huntington's disease pathogenesis

被引:9
作者
Gusella, James F.
MacDonald, Marcy
机构
[1] Massachusetts Gen Hosp, Ctr Human Genet Res, CPZN 5830, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Cambridge, MA 02138 USA
[3] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Boston, MA 02114 USA
关键词
Huntington's disease; genetics; neurodegeneration; modifier;
D O I
10.1016/j.brainresbull.2006.10.014
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Genetic analysis aims to identify the variations in DNA sequence whose functional consequences produce heritable variations in phenotype. In one of the first successes of unbiased molecular genetic analysis in human disease, the Huntington's disease (HD) gene was mapped and cloned without any prior knowledge of the nature of its protein product or of the molecular defect that underlies the characteristic phenotype of the disorder. However, while the cloning of HD and recognition of its trinucleotide repeat expansion spawned a plethora of approaches to investigating HD through its distinctive neuropathology, the: role for genetic strategies in HD research did not end there. The use of genetic analysis has remained a critical tool for defining the characteristics of the mechanism that triggers the pathogenic process, permitting the investigation of early events that occur long before traditionally recognized pathology. Delineation of these events can reveal molecular targets for development of therapies that prevent onset of HD. Most recently, an extension of genetic analysis to the identification of non-linked genetic variations that alter the course of HD pathogenesis has offered the promise of identifying modifier genes to reveal biological pathways active throughout the disease process and to provide valid targets for pharmacological intervention. Thus, unbiased genetic strategies have not only provided a crucial entree into molecular investigation of HD via a root cause that was previously unsuspected, they also represent a continuing route to accelerate the ultimate goal of developing an effective treatment for HD. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:78 / 82
页数:5
相关论文
共 36 条
[1]  
ANDREW S, 1993, CLIN GENET, V43, P286
[2]   Huntingtin aggregation and toxicity in Huntington's disease [J].
Bates, G .
LANCET, 2003, 361 (9369) :1642-1644
[3]  
BEAL MF, 1994, NEUROBIOL AGING, V15, P275
[4]   THE QUINOLINIC ACID HYPOTHESIS IN HUNTINGTON CHOREA [J].
BRUYN, RPM ;
STOOF, JC .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1990, 95 (01) :29-38
[5]   Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India [J].
Chattopadhyay, B ;
Ghosh, S ;
Gangopadhyay, PK ;
Das, SK ;
Roy, T ;
Sinha, KK ;
Jha, DK ;
Mukherjee, SC ;
Chakraborty, A ;
Singhal, BS ;
Bhattacharya, AK ;
Bhattacharyya, NP .
NEUROSCIENCE LETTERS, 2003, 345 (02) :93-96
[6]   Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain [J].
DiFiglia, M ;
Sapp, E ;
Chase, KO ;
Davies, SW ;
Bates, GP ;
Vonsattel, JP ;
Aronin, N .
SCIENCE, 1997, 277 (5334) :1990-1993
[7]   Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16 [J].
Djoussé, L ;
Knowlton, B ;
Hayden, MR ;
Almqvist, EW ;
Brinkman, RR ;
Ross, CA ;
Margolis, RL ;
Rosenblatt, A ;
Durr, A ;
Dode, C ;
Morrison, PJ ;
Novelletto, A ;
Frontali, M ;
Trent, RJA ;
McCusker, E ;
Gómez-Tortosa, E ;
Cabrero, DM ;
Jones, R ;
Zanko, A ;
Nance, M ;
Abramson, RK ;
Suchowersky, O ;
Paulsen, JS ;
Harrison, MB ;
Yang, Q ;
Cupples, LA ;
Mysore, J ;
Gusella, JF ;
MacDonald, ME ;
Myers, RH .
NEUROGENETICS, 2004, 5 (02) :109-114
[8]   Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease [J].
Djoussé, L ;
Knowlton, B ;
Hayden, M ;
Almqvist, EW ;
Brinkman, R ;
Ross, C ;
Margolis, R ;
Rosenblatt, A ;
Durr, A ;
Dode, C ;
Morrison, PJ ;
Novelletto, A ;
Frontali, M ;
Trent, RJA ;
McCusker, E ;
Gómez-Tortosa, E ;
Mayo, D ;
Jones, R ;
Zanko, A ;
Nance, M ;
Abramson, R ;
Suchowersky, O ;
Paulsen, J ;
Harrison, M ;
Yang, Q ;
Cupples, LA ;
Gusella, JF ;
MacDonald, ME ;
Myers, RH .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 119A (03) :279-282
[9]   TRINUCLEOTIDE REPEAT LENGTH INSTABILITY AND AGE-OF-ONSET IN HUNTINGTONS-DISEASE [J].
DUYAO, M ;
AMBROSE, C ;
MYERS, R ;
NOVELLETTO, A ;
PERSICHETTI, F ;
FRONTALI, M ;
FOLSTEIN, S ;
ROSS, C ;
FRANZ, M ;
ABBOTT, M ;
GRAY, J ;
CONNEALLY, P ;
YOUNG, A ;
PENNEY, J ;
HOLLINGSWORTH, Z ;
SHOULSON, I ;
LAZZARINI, A ;
FALEK, A ;
KOROSHETZ, W ;
SAX, D ;
BIRD, E ;
VONSATTEL, J ;
BONILLA, E ;
ALVIR, J ;
CONDE, JB ;
CHA, JH ;
DURE, L ;
GOMEZ, F ;
RAMOS, M ;
SANCHEZRAMOS, J ;
SNODGRASS, S ;
DEYOUNG, M ;
WEXLER, N ;
MOSCOWITZ, C ;
PENCHASZADEH, G ;
MACFARLANE, H ;
ANDERSON, M ;
JENKINS, B ;
SRINIDHI, J ;
BARNES, G ;
GUSELLA, J ;
MACDONALD, M .
NATURE GENETICS, 1993, 4 (04) :387-392
[10]   Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice [J].
Fossale, E ;
Wheeler, VC ;
Vrbanac, V ;
Lebel, LA ;
Teed, A ;
Mysore, JS ;
Gusella, JF ;
MacDonald, ME ;
Persichetti, F .
HUMAN MOLECULAR GENETICS, 2002, 11 (19) :2233-2241